Literature DB >> 11744810

Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins.

S Chen1, T Evans, D Deng, M Cukiernik, S Chakrabarti.   

Abstract

BACKGROUND/AIMS: Glomerular basement membrane (GBM) thickening and mesangial matrix expansion are characteristic features of diabetic nephropathy. The present study investigates the role of endothelins (ETs) in the pathogenesis of such changes in diabetic nephropathy.
METHODS: Diabetic (streptozotocin-induced, 65 mg/kg), galactose-fed (30%) and control animals were followed up for 1 and 6 months. Animal groups also included diabetic and galactose fed animals on dual ET(A)/ET(B) receptor antagonist bosentan (100 mg/kg). A semi-quantitative reverse transcription polymerase chain reaction method was used to quantify mRNA expression of ET-1, ET-3, ET(A), ET(B), fibronectin and collagen alpha2(IV). Histological analyses of the kidneys and ET-1, ET-3 and fibronectin immunohistochemistry were performed. Morphometric assessment of the GBM after 6 months was performed.
RESULTS: Diabetes increased mRNA expression of ET-1, ET-3, ET(A), ET(B), fibronectin and collagen alpha2(IV) after one and six months. In contrast, although increased ET(A) and ET(B) mRNAs were present following galactose feeding both at 1 and 6 months, ET-1, ET-3, fibronectin and collagen alpha2(IV)mRNAs were increased after 6 months. Both diabetes and galactose feeding caused increased GBM thickening. Furthermore, diabetes caused an increase in mesangial matrix production. Bosentan prevented increased fibronectin and collagen alpha2(IV) mRNA expression, increased mesangial matrix deposition and GBM thickening.
CONCLUSION: This study has demonstrated that diabetes and galactose feeding induced functional and structural changes in the kidney are mediated via ETs. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744810     DOI: 10.1159/000046319

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

1.  Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats.

Authors:  Yanfeng Ding; Ruijiao Zou; Robert L Judd; Juming Zhong
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

2.  Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.

Authors:  Gerald Wölkart; Heike Stessel; Zora Saad; Michael Kirchengast; Friedrich Brunner
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

3.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

4.  Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.

Authors:  Eugenia Raichlin; Abhiram Prasad; Verghese Mathew; Bailey Kent; David R Holmes; Geralyn M Pumper; Rebecca E Nelson; Lilach O Lerman; Amir Lerman
Journal:  Hypertension       Date:  2008-08-11       Impact factor: 10.190

5.  The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Authors:  A M D Watson; J Li; C Schumacher; M de Gasparo; B Feng; M C Thomas; T J Allen; M E Cooper; K A M Jandeleit-Dahm
Journal:  Diabetologia       Date:  2009-10-28       Impact factor: 10.122

6.  Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes.

Authors:  Arjun Jain; Shali Chen; Hannah Yong; Subrata Chakrabarti
Journal:  J Diabetes Metab Disord       Date:  2018-10-18

7.  Differential effects of curcumin on vasoactive factors in the diabetic rat heart.

Authors:  Hana Farhangkhoee; Zia A Khan; Shali Chen; Subrata Chakrabarti
Journal:  Nutr Metab (Lond)       Date:  2006-07-18       Impact factor: 4.169

8.  SIRT1 reduction causes renal and retinal injury in diabetes through endothelin 1 and transforming growth factor β1.

Authors:  Rokhsana Mortuza; Biao Feng; Subrata Chakrabarti
Journal:  J Cell Mol Med       Date:  2015-03-06       Impact factor: 5.310

9.  Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture.

Authors:  Richard Filek; Phil Hooper; Tom G Sheidow; Hong Liu; Subrata Chakrabarti; Cindy Ml Hutnik
Journal:  Clin Ophthalmol       Date:  2019-07-01

10.  Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency.

Authors:  Suvi Törmänen; Päivi Lakkisto; Arttu Eräranta; Peeter Kööbi; Ilkka Tikkanen; Onni Niemelä; Jukka Mustonen; Ilkka Pörsti
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.